Development of TRAIL-R2 synthetic trimer agonists for cancer therapy

被引：0
|
作者：
Angell, Y. M.
Frederick, B. T.
Green, J.
Schatz, P. J.
Whitehorn, E. A.
Wright, K. L.
Holmes, C. H.
机构：
[1] Affymax Inc, Dept Chem, Palo Alto, CA 94304 USA
[2] Affymax Inc, Dept Biol, Palo Alto, CA 94304 USA
来源：
BIOPOLYMERS | 2007年 / 88卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：532 / 532
页数：1
相关论文
共 50 条
  • [31] Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
    Harald Wajant
    Dieter Moosmayer
    Thomas Wüest
    Till Bartke
    Elke Gerlach
    Ulrike Schönherr
    Nathalie Peters
    Peter Scheurich
    Klaus Pfizenmaier
    Oncogene, 2001, 20 : 4101 - 4106
  • [32] TRAIL or TRAIL-R2 as a Predictive Biomarker for Mortality or Cardiovascular Events: A Systematic Review and Meta-analysis
    Kuang, Na
    Shu, Bingjun
    Yang, Fengjing
    Li, Song
    Zhang, Mingxi
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2023, 81 (05) : 348 - 354
  • [33] Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis
    Mori, E
    Thomas, M
    Motoki, K
    Kataoka, S
    FEBS LETTERS, 2005, 579 (24): : 5379 - 5384
  • [34] Decreased placental and maternal serum TRAIL-R2 levels are associated with placenta accreta
    Oztas, Efser
    Ozler, Sibel
    Ersoy, Ali Ozgur
    Ersoy, Ebru
    Caglar, Ali Turhan
    Uygur, Dilek
    Yucel, Aykan
    Ergin, Merve
    Danisman, Nuri
    PLACENTA, 2016, 39 : 1 - 6
  • [35] The cancer testis antigen MAGED2 protects human melanoma cells from TRAIL-induced apoptosis by suppressing TRAIL-R2 expression
    Tseng, Hsin-Yi
    Chen, Li Hua
    Ye, Yan
    Jiang, Chen Chen
    Hersey, Peter
    Zhang, Xu Dong
    CANCER RESEARCH, 2012, 72
  • [36] Bortezomib-mediated up-regulation of TRAIL-R1 and TRAIL-R2 (November, pg 6541, 2007)
    Koschny, Ronald
    Holland, Heidrun
    Sykora, Jaromir
    Haas, Tobias L.
    Sprick, Martin R.
    Ganten, Tom M.
    Krupp, Wolfgang
    Bauer, Manfred
    Ahnert, Peter
    Meixensberger, Juergen
    Walczak, Henning
    CLINICAL CANCER RESEARCH, 2007, 13 (23) : 7224 - 7224
  • [37] INVOLVEMENT OF ENDOCYTOSIS IN TRAIL-R1/DR4 AND TRAIL-R2/DR5 TRAFFICKING AND SIGNALING
    Sourkova, V
    Andera, L.
    ADVANCES IN TNF FAMILY RESEARCH, 2011, 691 : 815 - 816
  • [38] Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
    Wajant, H
    Moosmayer, D
    Wüest, T
    Bartke, T
    Gerlach, E
    Schönherr, U
    Peters, N
    Scheurich, P
    Pfizenmaier, K
    ONCOGENE, 2001, 20 (30) : 4101 - 4106
  • [39] TRAIL-R2 and HRK Mediate Angiotensin Type 2 Receptor-Induced Apoptosis of Human Prostate Cancer Cells
    Pei, Nana
    Zhang, Yanling
    Jie, Feilong
    Luo, Jie
    Chen, Xinglu
    Li, Jinlong
    Li, Hongwei
    MOLECULAR THERAPY, 2013, 21 : S86 - S86
  • [40] The selective targeting of myeloid-derived suppressor cells in cancer patients using an agonistic TRAIL-R2 antibody
    Dominguez, George A.
    Condamine, Thomas
    Mony, Sridevi
    Hashimoto, Ayumi
    Wang, Fang
    Liu, Qin
    Forero, Andres
    Bendell, Johanna C.
    Witt, Robert
    Hockstein, Neil
    Kumar, Prasanna
    Gabrilovich, Dmitry I.
    CANCER RESEARCH, 2017, 77
12345